BioSpace News Archive

Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company discovering and developing Pentarins™ as a new class of potent and selective cancer medicines, today announced that the company will present preclinical data related to PEN-866 at the 2018 American Association for Cancer Research (AACR) Annual Meeting, occurring April 14-18, 2018 in Chicago, IL

Acoustic droplet ejection technology uses the gentle energy of sound waves to move liquids at nanoliter resolution with superior precision and accuracy.

Two platform presentations and 19 posters explore the potential of fremanezumab as an investigational treatment option for the prevention of migraine COPAXONE® (glatiramer acetate injection) and AUSTEDO® (deutetrabenazine) tablets data highlight Teva’s ongoing clinical research

Data show ability of destabilizing domain technology platform to regulate expression of secreted and membrane-bound proteins in cell therapies

Lm platform targets common mutations in tumor driver genes.

Data from TOUR™ Observational Patient Registry Highlights Positive Clinical Response Rates in Elderly and Obese Patients Additional VIBATIV Study Results Demonstrate Greater in vitro Potency than Competitor Antibiotics Against Difficult-to-Treat Staphylococcus aureus Pathogens including Challenging Multidrug Resistant (MDR) MRSA Isolates

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the company is beginning two Phase 3 studies of PCV-15 (V114), its investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease.

Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, today presents preclinical data on the immune activating antibody ATOR-1015 at the American Association of Cancer Research (AACR) Annual Meeting 2018 taking place in Chicago, Illinois.

Altan Pharma Limited (“Altan”), an Irish specialty pharmaceutical company, today announced that the United States Patent and Trademark Office (“USPTO”) has granted two patents to Altan covering its intravenous formulation of acetaminophen (paracetamol).

University of Nevada, Reno School of Medicine researcher finds new molecular link between type 2 diabetes and obesity that may lead to targeted drug treatments